Jaypirca (Pirtobrutinib) Patent Expiration, LOE Window & CMS Spending
Jaypirca (Pirtobrutinib) by Eli Lilly: FDA Orange Book core substance LOE 2036-12-16 (last listed 2041-09-14), 0 AB generics, $207.0M 2024 CMS Part D & Medicaid spend, and $21,000 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eli Lilly |
| FDA Application & Pathway | N216059 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2036-12-16 |
| Last Listed Patent or Exclusivity Date | 2041-09-14 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $207.0M |
| 2024 Medicare Part D Spend | $200.6M |
| 2024 Medicaid Spend | $6.5M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($21,000 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.